Story perspectives

FDA Approves Compounded Weight-Loss Drugs Amid Shortages

9/21/2025

37 8

Summary

Story summary

The FDA permitted compounded GLP-1 weight-loss drugs due to shortages of brand-name options like Ozempic and Wegovy.
Although the FDA claims shortages are resolved, some companies exploit loopholes to sell compounded drugs.
High costs of FDA-approved drugs drive patients to seek cheaper compounded alternatives.
States, including Ohio, are tightening regulations on compounding, while drugmakers pursue legal action against compounders.
Compounded drugs lack FDA approval, raising safety concerns and prompting warnings about misleading advertising.

1 of 1

Story summary

The FDA permitted compounded GLP-1 weight-loss drugs due to shortages of brand-name options like Ozempic and Wegovy.
Although the FDA claims shortages are resolved, some companies exploit loopholes to sell compounded drugs.
High costs of FDA-approved drugs drive patients to seek cheaper compounded alternatives.
States, including Ohio, are tightening regulations on compounding, while drugmakers pursue legal action against compounders.
Compounded drugs lack FDA approval, raising safety concerns and prompting warnings about misleading advertising.